A selective VEGFR-3 inhibitor may be beneficial when compared to already developed pan-VEGFR inhibitors due to lower toxicity. Finally, identification of potential responders to selective anti-VEGFR-3 ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor camrelizumab can enter the U.S. market. | The FDA has once again ...

A 35-year-old woman was admitted at 8 weeks postpartum because of shortness of breath and edema in the legs. Proteinuria had developed at the end of the pregnancy. A diagnosis was made.

Ideally, PlGF could be used to screen younger populations for whom currently available treatments and lifestyle modifications may prevent or reverse the deleterious effects of vascular injury ...

After the approval of belzutifan in the United States for patients with advanced renal-cell carcinoma who had previously received a PD-1 or PD-L1 inhibitor and a VEGFR-TKI, the drug could be used ...

Surprisingly, the PlGF-mediated improvement in collateral numbers and perfusion was superior when compared with the VEGFR-2–specific ligand VEGF-E and displayed no additive activities when combined ...

Treatment with oral VEGFR-TKIs may carry an increased risk of aneurysm and artery dissection. Tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR-TKIs) are ...

The Triage PLGF test delivers results in approximately 15 minutes and provides high accuracy to support the clinical diagnosis of pre-eclampsia needing delivery within 14 days.

A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found.